ArticleJournal of virology2004
Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1.
Article in Journal of virology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 60 citations in OpenAlex.
- Recombinant Live-AttenuatedVaccines · 2024Review
- Review
- Attenuated Salmonella carrying plasmid co-expressing HPV16 L1 and siRNA-E6 for cervical cancer therapy.Scientific reports · 2021Article
- The rabbit papillomavirus model: a valuable tool to study viral-host interactions.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2019Review
- Evaluation of the Effect of Promoter Type on the Immunogenicity of the Live RecombinantIranian journal of pharmaceutical research : IJPR · 2018Article
- A Live Vector Expressing HPV16 L1 Generates an Adjuvant-Induced Antibody Response In-vivo.Iranian journal of cancer prevention · 2015Article
- Article
- Surface display of the HPV L1 capsid protein by the autotransporter Shigella IcsA.Journal of microbiology (Seoul, Korea) · 2014Article
- Recombinant Salmonella enterica serovar Typhimurium as a vaccine vector for HIV-1 Gag.Viruses · 2013Review
- New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention.Antiviral therapy · 2012Review
- Enhancement of cancer vaccine therapy by systemic delivery of a tumor-targeting Salmonella-based STAT3 shRNA suppresses the growth of established melanoma tumors.Cancer research · 2011Article
- HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future.Journal of translational medicine · 2010Review
- Papillomavirus prophylactic vaccines: established successes, new approaches.Journal of virology · 2010Review
- Oral vaccination with a recombinant Salmonella vaccine vector provokes systemic HIV-1 subtype C Gag-specific CD4+ Th1 and Th2 cell immune responses in mice.Virology journal · 2009Article
- HPV Vaccines: today and in the Future.The Journal of adolescent health : official publication of the Society for Adolescent Medicine · 2008Review
- Intravaginal immunization of mice with recombinant Salmonella enterica serovar Typhimurium expressing human papillomavirus type 16 antigens as a potential route of vaccination against cervical cancer.Infection and immunity · 2008Article
- Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer.Biologics : targets & therapy · 2008Article
- Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.Clinical and vaccine immunology : CVI · 2007Article
- How will HPV vaccines affect cervical cancer?Nature reviews. Cancer · 2006Review
- Papillomavirus genome structure, expression, and post-transcriptional regulation.Frontiers in bioscience : a journal and virtual library · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer results from cervical infection by human papillomaviruses (HPVs), especially HPV16. An effective vaccine against these HPVs is expected to have a dramatic impact on the incidence of this cancer and its precursor lesions. The leading candidate, a subunit prophylactic HPV virus-like particle (VLP) vaccine, can protect women from HPV infection. An alternative improved vaccine that avoids parenteral injection, that is efficient with a single dose, and that induces mucosal immunity might greatly facilitate vaccine implementation in different settings. In this study, we have constructed a new generation of recombinant Salmonella organisms that assemble HPV16 VLPs and induce high titers of neutralizing antibodies in mice after a single nasal or oral immunization with live bacteria. This was achieved through the expression of a HPV16 L1 capsid gene whose codon usage was optimized to fit with the most frequently used codons in Salmonella. Interestingly, the high immunogenicity of the new recombinant bacteria did not correlate with an increased expression of L1 VLPs but with a greater stability of the L1-expressing plasmid in vitro and in vivo in absence of antibiotic selection. Anti-HPV16 humoral and neutralizing responses were also observed with different Salmonella enterica serovar Typhimurium strains whose attenuating deletions have already been shown to be safe after oral vaccination of humans. Thus, our findings are a promising improvement toward a vaccine strain that could be tested in human volunteers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.